An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart and Mirikizumab for the Treatment of Adult Patients with Moderately to Severely Active Ulcerative Colitis

The primary purpose of this study is to determine differences in proportions of participants achieving clinical remission at Week 12, comparing eltrekibart versus placebo, in adult patients with moderate-to-severe UC. This will be followed by a 40-week Maintenance Period to explore safety and the durability of remission.